Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Travere Therapeutics, Inc.
TVTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.2B
$55.72
▼ -1.11%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$14.44 - $60.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 279.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established portfolio of FDA-approved rare disease medications with limited competition
- Specialized expertise in rare metabolic and genetic disorder treatment
- Strategic partnerships with NIH and patient advocacy organizations for drug discovery
- Orphan drug designations providing regulatory and market exclusivity benefits
Bear Case
2 risks
- Average volatility.
- Growth premium of 2.8x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Turning profitable
Sparsentan Phase III clinical trial advancement for FSGS and IgA nephropathy treatment
Value
Growth premium of 2.8x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+85.1% over 3m
Quality
Excellent
High-growth business (96% revenue growth, 94% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TVTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 4, 2026
Reported EPS of -$0.39 vs -$0.24 consensus (-61.1% surprise). Revenue of $127.2M vs $136.2M expected (-6.6%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-61.1%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+66%
+98%
+111%
+162%
+73%
+56%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$54.1M
$62.9M
$74.8M
$81.7M
$114.4M
$164.9M
$129.7M
$127.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-29.2%
Wall Street consensus
9 analysts · 89% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
89%
Hold
11%
Sell
0%
Median Price Target
$54.00
▼ -3.1% vs $55.72
Latest: Guggenheim · Jun 25, 2026
3 analysts covering